Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AKBA

Akebia Therapeutics Inc.

Sep 06 • 04:00PM ET

1.35

Dollar change -0.03
Percentage change -2.17	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWC FESM ITOT GSSC IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.20	Insider Own	5.04%	Shs Outstand	210.29M	Perf Week	-11.18%
Market Cap	283.89M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	-0.69%	Shs Float	199.68M	Perf Month	21.62%
Income	-40.44M	PEG	-	EPS next Q	-0.06	Inst Own	24.16%	Short Float	9.49%	Perf Quarter	26.17%
Sales	174.50M	P/S	1.63	EPS this Y	13.10%	Inst Trans	-8.77%	Short Ratio	6.70	Perf Half Y	-7.53%
Book/sh	-0.16	P/B	-	EPS next Y	-5.48%	ROA	-17.07%	Short Interest	18.95M	Perf Year	8.00%
Cash/sh	0.19	P/C	7.19	EPS next 5Y	-	ROE	-554.87%	52W Range	0.78 - 2.48	Perf YTD	8.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	35.46%	ROI	-63.51%	52W High	-45.56%	Beta	0.80
Dividend TTM	-	Quick Ratio	0.82	Sales past 5Y	5.16%	Gross Margin	61.67%	52W Low	73.05%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.04	EPS Y/Y TTM	62.08%	Oper. Margin	-20.11%	RSI (14)	45.89	Volatility	8.13% 7.61%
Employees	167	Debt/Eq	-	Sales Y/Y TTM	-12.98%	Profit Margin	-23.18%	Recom	1.00	Target Price	5.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	31.61%	Payout	-	Rel Volume	0.60	Prev Close	1.38
Sales Surprise	-12.45%	EPS Surprise	44.67%	Sales Q/Q	-22.58%	Earnings	Aug 08 BMO	Avg Volume	2.83M	Price	1.35
SMA20	-4.85%	SMA50	3.88%	SMA200	0.14%	Trades		Volume	1,692,148	Change	-2.17%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Resumed	BTIG Research	Buy	$4
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$3.75
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral	$8 → $2
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Mizuho	Buy → Neutral	$6 → $2
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $2
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight	$8
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy	$18 → $15
Aug-06-19	Reiterated	H.C. Wainwright	Buy	$19 → $17
Jul-11-19	Reiterated	H.C. Wainwright	Buy	$23 → $21
May-02-19	Initiated	JP Morgan	Overweight	$12
Mar-20-19	Initiated	Citigroup	Neutral	$9
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy	$20 → $18
Jun-06-18	Reiterated	H.C. Wainwright	Buy	$24 → $22
Dec-19-17	Initiated	Piper Jaffray	Overweight	$26
Dec-07-17	Initiated	BTIG Research	Buy	$30
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform	$17

Show Previous Ratings

Sep-05-24 08:00AM	Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo (vadadustat) for Patients on Dialysis (PR Newswire)
Sep-03-24 04:16PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -9.03%
Aug-26-24 10:45AM	Here's Why You Should Consider Buying Akebia (AKBA) Stock (Zacks)
08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Aug-08-24 08:10AM	Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +7.21%
07:09AM	Loading…
07:09AM	Akebia Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
Aug-02-24 08:00AM	Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights (PR Newswire)
Aug-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.52%
Jul-29-24 08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Jul-11-24 06:00AM	Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo (vadadustat) Tablets (PR Newswire) +17.59%
Jul-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-27-24 08:18AM	Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference (PR Newswire) +6.98%
Jun-24-24 08:58AM	Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer (PR Newswire)
Jun-03-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
08:00AM	Loading…
May-23-24 08:00AM	Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-14-24 08:00AM	Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference (PR Newswire)
May-10-24 03:27PM	Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview (GuruFocus.com) -9.02%
03:06PM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:57AM	AKBA Stock Earnings: Akebia Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:09AM	Akebia Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
May-02-24 08:30AM	Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights (PR Newswire)
May-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-02-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.70%
Mar-28-24 11:50AM	FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia (Benzinga) -18.30%
07:06AM	Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD (Zacks)
Mar-27-24 08:26PM	Akebia Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis (PR Newswire) +12.00%
Mar-26-24 01:12PM	Akebia Awaits FDA Word On Second Crack At Vadadustat (Barrons.com) -9.50%
09:53PM	Loading…
Mar-14-24 09:53PM	AKBA Stock Earnings: Akebia Therapeutics Beats Revenue for Q4 2023 (InvestorPlace) +24.09%
05:51PM	Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter (GuruFocus.com)
05:30PM	Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4 (Zacks)
04:15PM	Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (PR Newswire)
Mar-11-24 05:05PM	Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-01-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.23% -5.26%
Feb-02-24 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-30-24 08:00AM	Akebia Secures $55 Million Term Loan Financing (PR Newswire) -8.38%
Jan-09-24 08:30AM	Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer (PR Newswire)
Jan-02-24 04:30PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.87%
Dec-20-23 08:00AM	Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-01-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.48%
10:00AM	Top Penny Stocks for Q4 2023 (Investopedia)
Nov-20-23 08:00AM	Akebia Therapeutics to Present at Piper Sandler Healthcare Conference (PR Newswire)
Nov-09-23 11:32AM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.20%
Nov-08-23 10:05PM	Q3 2023 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.93%
07:40AM	Akebia Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
Nov-02-23 04:30PM	Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors (PR Newswire) +6.95%
Nov-01-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-31-23 08:00AM	Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights (PR Newswire)
Oct-26-23 10:02AM	Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-25-23 08:30AM	Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease (PR Newswire) -6.65%
Oct-18-23 08:00AM	Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023 (PR Newswire)
Oct-03-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.70% +5.71%
Sep-28-23 08:00AM	Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat (PR Newswire)
Sep-26-23 08:00AM	Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update (PR Newswire)
Sep-06-23 08:00AM	Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference (PR Newswire)
Sep-05-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.27%
Aug-31-23 06:15AM	The Petri Dish: Boston Scientific device succeeds in trial, Sanofi vet joins Flagship (American City Business Journals)
Aug-28-23 12:18PM	Is Akebia Therapeutics Inc (AKBA) Set to Underperform? Analyzing the Factors Limiting Growth (GuruFocus.com) +20.00%
11:44AM	Unveiling Akebia Therapeutics (AKBA)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
08:12AM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-25-23 10:25PM	Q2 2023 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -8.00%
09:40AM	Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:28AM	Akebia Therapeutics: Q2 Earnings Snapshot (AP Finance)
08:09AM	Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
Aug-24-23 08:00AM	Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 (PR Newswire)
Aug-23-23 04:35PM	Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights (PR Newswire)
Aug-17-23 04:05PM	Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023 (PR Newswire)
Aug-10-23 05:40PM	Akebia Therapeutics Provides Update on Form 10-Q Filing (PR Newswire) -14.29%
Aug-01-23 04:30PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +10.18% -5.98%
Jul-26-23 09:40AM	Are Medical Stocks Lagging InMode (INMD) This Year? (Zacks)
Jul-19-23 07:45AM	Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference (PR Newswire) +5.98%
Jul-18-23 07:45AM	Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023 (PR Newswire)
Jul-06-23 06:07AM	Pocket Change, Big Gains: 3 Penny Stocks Ready to Boom (InvestorPlace)
Jul-04-23 07:34AM	Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26% (Zacks)
Jun-29-23 08:00AM	Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients (PR Newswire)
Jun-27-23 09:50AM	Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89% (Zacks)
Jun-21-23 08:35AM	Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera (Zacks)
Jun-20-23 08:00AM	Akebia Announces Swissmedic Approval of Vafseo® (vadadustat) (PR Newswire)
Jun-19-23 09:40AM	Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-13-23 07:00AM	Akebia Therapeutics Announces New Chief Financial Officer (PR Newswire)
Jun-08-23 01:20PM	Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been splendid, earning 188% in 1 year (Simply Wall St.)
09:19AM	Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data (Zacks)
Jun-02-23 12:00PM	All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy (Zacks)
09:40AM	Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year? (Zacks)
08:30AM	Akebia Therapeutics to Present at Jefferies Healthcare Conference (PR Newswire)
Jun-01-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-30-23 07:30AM	FDA Provides Akebia Therapeutics a Path Forward for Vadadustat (PR Newswire) -15.17%
May-25-23 08:00AM	Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia (PR Newswire) -15.38%
May-23-23 11:27AM	Why Shares of Akebia Therapeutics Were Up Tuesday (Motley Fool)
May-22-23 05:15PM	Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) +21.55%
08:30AM	Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis (PR Newswire)
May-10-23 09:40AM	Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-09-23 02:12AM	Q1 2023 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 08:45AM	Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
May-04-23 10:00AM	Will CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know (Zacks) +5.67%
May-01-23 10:01AM	Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know (Zacks)

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hadas Nicole R.	SVP, Chief Legal Officer	May 13 '24	Sale	1.26	12,016	15,140	651,243	May 14 04:05 PM
Dahan Michel	SVP, Chief Operating Officer	May 13 '24	Sale	1.26	34,840	43,898	672,092	May 14 04:04 PM
Dahan Michel	SVP, Chief Operating Officer	Feb 29 '24	Sale	1.58	8,661	13,684	706,932	Mar 01 05:49 PM
Hadas Nicole R.	SVP, Chief Legal Officer	Feb 29 '24	Sale	1.58	5,974	9,439	663,259	Mar 01 05:48 PM
Butler John P.	CEO and President	Feb 29 '24	Sale	1.58	46,570	73,581	2,044,580	Mar 01 05:47 PM
Burke Steven Keith	SVP, Chief Medical Officer	Feb 29 '24	Sale	1.58	7,169	11,327	695,840	Mar 01 05:46 PM
Hadas Nicole R.	SVP, Chief Legal Officer	Feb 27 '24	Sale	1.52	7,411	11,265	669,233	Feb 29 06:03 PM
Dahan Michel	SVP, Chief Operating Officer	Feb 27 '24	Sale	1.52	10,744	16,331	715,593	Feb 29 06:02 PM
Burke Steven Keith	SVP, Chief Medical Officer	Feb 27 '24	Sale	1.52	8,367	12,718	703,009	Feb 29 06:01 PM
Butler John P.	CEO and President	Feb 27 '24	Sale	1.52	37,733	57,354	2,091,150	Feb 29 06:00 PM
Butler John P.	CEO and President	Feb 01 '24	Sale	1.68	46,489	78,102	2,128,883	Feb 02 04:10 PM
Burke Steven Keith	SVP, Chief Medical Officer	Feb 01 '24	Sale	1.68	24,311	40,842	711,376	Feb 02 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKBA

Akebia Therapeutics Inc.

Upgrade your FINVIZ experience